多只生物股逆市再破顶 康方生物(09926.HK)反覆续涨逾半成高见37.45元
将於下周一挂牌的两只医药相关股海吉亚医疗(06078.HK)及康基医疗(09997.HK)招股反应热烈,其中公开发售分别获逾600-980倍超购,认购一手中签率仅约9%。多只影子生物股今早股价再破顶创上市新高,包括药明生物(02269.HK)及百济神州(06160.HK)分别高见150.6元及134.4元。
康方生物(09926.HK)也连续第二天反覆创上市新高,该股今早随大市低开报34.6元获承接,掉头突破周三盘中所创上市高位35.5元,最高见37.45元,半日收36.9元,逆市续升5.3%,成交265万股。
康方是一家临床阶段生物制药公司,致力於自主发现、开发及商业化首创及同类最佳疗法,并专注於满足肿瘤、免疫及其他治疗领域在全球未决医疗需求。股份於今年4月24日以每股16.18元上市。康方本月中先後公布自主研发新药AK120(用於特应性皮炎及哮喘等过敏性疾病)及AK109(用於晚期实体瘤)均已完成首例患者入组给药。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.